Any current/future new fundraising through debt or equity?

No significant increase in debt is expected; the current debt level is comfortable. Debt has come down as of September compared to March. For FY25-26, INR130 crores of debt repayment is expected, and the company plans to maintain similar debt levels. Capex for the Pharma division will continue, partly funded by borrowing, but overall debt is expected to remain stable around INR800 crores. No mention of any planned equity fundraising in the disclosed communication.

Future growth expectations in earnings/operating earnings/profits/EPS?

Hikal Limited is optimistic about stronger H2 FY25 performance compared to H1, following historical trends, driven by seasonal and customer dynamics. FY26 is expected to see growth in both revenue and EBITDA margins, particularly from the Pharma division. Crop Protection is anticipated to recover with improvements starting possibly in H2 FY26, with the worst phase believed to be behind. New Pharma capacity will come on stream next year but will take 1-2 years to reach commercial operations. The company is not providing explicit forward-looking guidance or numerical forecasts due to uncertainti

Any current/future capex/capital investment/strategic investment?

Hikal Limited is putting up new capacity primarily on the Pharma side, which will come on stream next year but will take 1-2 years to commercialize and become operational. The company continues to invest in assets in the Pharma division while maintaining a comfortable debt position. Capex plans primarily focus on the Pharma business. Debt is expected to stay around INR 800 crores with repayments planned (INR 130 crores in FY25-26). Hikal is expanding its front-end presence by onshoring personnel and setting up offices in North America, Europe, Japan, and Latin America to boost new busi

Future growth expectations in sales/revenue/volumes?

Pharma division expects positive momentum with revenue and volume growth continuing into H2 FY25 and further improving in FY26, supported by new product launches and increased CDMO orders. Crop Protection division anticipates stabilization with volume growth recovering, expected to improve margins by H2 FY26 as excess inventory issues resolve. Overall, stronger H2 FY25 anticipated compared to H1 FY25; FY26 projected to be stronger than FY25. No specific forward-looking growth guidance provided due to uncertainty in Crop division. Company focused on capacity expansion in Pharma, with new capaci

Current/ Expected Orderbook/ Pending Orders?

Hikal Limited is witnessing increased traction in CDMO customers with more inquiries and requests for proposals (RFPs), notably from the U.S., Europe, and Japan. There has been a significant increase (around 50% higher than last year) in customer audits, indicating growing interest and pending orders in the CDMO segment. Commercial supplies for several validated products, including animal health APIs, are expected to start in the second half of calendar year 2025. The company has a robust CDMO pipeline with around seven crop protection products from existing and potential clients. New business

HikalQ2 FY25Pharmaceuticals & Biotechnology

Hikal Q2 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹218P/E: 63.3Market Cap: ₹2.7K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 4

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 4

Pharma division expects positive momentum with revenue and volume growth continuing into H2 FY25 and further improving in FY26, supported by new product launches and increased CDMO orders.
Crop Protection division anticipates stabilization with volume growth recovering, expected to improve margins by H2 FY26 as excess inventory issues resolve.
Overall, stronger H2 FY25 anticipated compared to H1 FY25; FY26 projected to be stronger than FY25.
No specific forward-looking growth guidance provided due to uncertainty in Crop division.
Company focused on capacity expansion in Pharma, with new capacity coming online next year (commercialization 1-2 years post-launch).
Emphasis on acquiring new customers, technological advancements, and broadening geographic presence to drive sustainable, profitable growth.

Margin guidance

Category 3

Hikal Limited is optimistic about stronger H2 FY25 performance compared to H1, following historical trends, driven by seasonal and customer dynamics.
FY26 is expected to see growth in both revenue and EBITDA margins, particularly from the Pharma division.
Crop Protection is anticipated to recover with improvements starting possibly in H2 FY26, with the worst phase believed to be behind.
New Pharma capacity will come on stream next year but will take 1-2 years to reach commercial operations.
The company is not providing explicit forward-looking guidance or numerical forecasts due to uncertainties, particularly in the Crop division.
Continued focus on cost efficiencies, operational improvements, and new product launches in Pharma supports positive profitability momentum.
Overall, management expects long-term sustainable growth driven by strategic initiatives and improving margin profiles.

See what Hikal management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes

No significant increase in debt is expected; the current debt level is comfortable.
Debt has come down as of September compared to March.
For FY25-26, INR130 crores of debt repayment is expected, and the company plans to maintain similar debt levels.
Capex for the Pharma division will continue, partly funded by borrowing, but overall debt is expected to remain stable around INR800 crores.
No mention of any planned equity fundraising in the disclosed communication.

Order book

Hikal Limited is witnessing increased traction in CDMO customers with more inquiries and requests for proposals (RFPs), notably from the U.S., Europe, and Japan.
There has been a significant increase (around 50% higher than last year) in customer audits, indicating growing interest and pending orders in the CDMO segment.
Commercial supplies for several validated products, including animal health APIs, are expected to start in the second half of calendar year 2025.
The company has a robust CDMO pipeline with around seven crop protection products from existing and potential clients.
New business acquisition efforts include onshoring teams in North America, Europe, Japan, and setting up an office in Latin America to be closer to customers.
Q3 orders may be subdued due to customer shipment timing but are expected to pick up strongly in Q4 and beyond, with H2 FY25 anticipated to be stronger than H1 FY25.

See what Hikal management said on order book — free account, 30 seconds.

Capex plans

Yes

Hikal Limited is putting up new capacity primarily on the Pharma side, which will come on stream next year but will take 1-2 years to commercialize and become operational.
The company continues to invest in assets in the Pharma division while maintaining a comfortable debt position.
Capex plans primarily focus on the Pharma business.
Debt is expected to stay around INR 800 crores with repayments planned (INR 130 crores in FY25-26).
Hikal is expanding its front-end presence by onshoring personnel and setting up offices in North America, Europe, Japan, and Latin America to boost new business acquisition.
Continuous R&D investment of about 4-5% of revenue is maintained to foster innovation and technology development.
The strategic initiatives include Project Pinnacle aimed at profitable and sustainable growth across all segments.

Track Hikal — get its next earnings analysis in your feed

How does Hikal rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisHikal

Rev 4Mar 3

See where Hikal sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Hikal rank in Pharmaceuticals & Biotechnology?

Compare Hikal against every Pharmaceuticals & Biotechnology company (Q2 FY25) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Hikal's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Natural Capsules Ltd (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
RPG Life Sciences Ltd (Q2 FY25)
Q2 FY25: ₹172.2 Crores . Key concall takeaways from RPG Life Sciences Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Sun Pharma.Inds.vs Divis Laboratories Ltd vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →